… In this study, the survival of treatment-naïve patients with aNSCLC who received anlotinib
monotherapy was promising. Also, patients with aNSCLC who received a combination of …

… 25.0% and 70.37% in those who received anlotinib monotherapy or anlotinib combined with
chemotherapy, respectively (Table 3). The mPFS of monotherapy was 1.20 months (95% CI: …

… Anlotinib monotherapy or combination therapy can be more effective and safer for certain
advanced sarcomas, with more extended maintenance and acceptable side effects. Clinical …

… (stage IIIB-IV) receiving anlotinib between November 2018 and February 2020 … safety of
overall patients were evaluated, and the efficacies of anlotinib plus immunotherapy and anlotinib …

… Profile of the 83 Elderly Patients with Advanced NSCLC Receiving Anlotinib Monotherapy
The maximum toxicity of the 83 elderly patients experienced during anlotinib monotherapy …

… All the patients were administered with anlotinib monotherapy. Demographic data of the
patients were collected; effectiveness and safety profile during anlotinib monotherapy were …

… in the observation group administered with anlotinib and PD-1/… group administered with
paclitaxel monotherapy as second-… Clinical characteristics of the group that received anlotinib …

… anlotinib with chemotherapy prolonged PFS and OS as compared to anlotinib monotherapy
… the chemotherapy combination regimen compared to anlotinib monotherapy (3.6 months vs. …

… Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted
to assess efficacy and safety of anlotinib … the efficacy and safety of anlotinib in patients with …

… anlotinib monotherapy and 14 were treated with anlotinib … showed longer PFS compared
with monotherapy group (8.40m vs… % (1/6) in the monotherapy group and the DCR was 87.5% (…